US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
AU1238500A
(en)
*
|
1998-11-02 |
2000-05-22 |
Alza Corporation |
Controlled delivery of active agents
|
JP2002534139A
(ja)
*
|
1999-01-05 |
2002-10-15 |
マサチューセッツ・アイ・アンド・イア・インファーマリー |
網膜と脈絡膜への経強膜徐放性薬剤標的送達
|
WO2001043721A2
(en)
|
1999-12-16 |
2001-06-21 |
Alza Corporation |
Dosage forms having a barrier layer to laser ablation
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
US6923927B2
(en)
*
|
2000-10-03 |
2005-08-02 |
Atrium Medical Corporation |
Method for forming expandable polymers having drugs or agents included therewith
|
US6616876B1
(en)
*
|
2000-10-03 |
2003-09-09 |
Atrium Medical Corporation |
Method for treating expandable polymer materials
|
IL162666A0
(en)
*
|
2001-12-28 |
2005-11-20 |
Teva Pharma |
A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
|
WO2004026235A2
(en)
*
|
2002-09-20 |
2004-04-01 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical compositions with improved dissolution
|
US20100311701A1
(en)
*
|
2002-02-15 |
2010-12-09 |
Transform Pharmaceuticals, Inc |
Pharmaceutical Co-Crystal Compositions
|
WO2004078161A1
(en)
|
2003-02-28 |
2004-09-16 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
US7790905B2
(en)
*
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
US7927613B2
(en)
*
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
US6559293B1
(en)
*
|
2002-02-15 |
2003-05-06 |
Transform Pharmaceuticals, Inc. |
Topiramate sodium trihydrate
|
CA2477923C
(en)
*
|
2002-03-01 |
2021-02-23 |
University Of South Florida |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
AU2003224794A1
(en)
*
|
2002-03-29 |
2003-10-13 |
Alza Corporation |
Volume efficient controlled release dosage form
|
WO2003092665A2
(en)
*
|
2002-05-02 |
2003-11-13 |
Massachusetts Eye And Ear Infirmary |
Ocular drug delivery systems and use thereof
|
WO2003096968A2
(en)
*
|
2002-05-15 |
2003-11-27 |
Sun Pharmaceutical Industries Limited |
Oral osmotic controlled drug delivery system
|
KR100897890B1
(ko)
|
2002-06-17 |
2009-05-18 |
인벤티아 헬스케어 피브이티. 엘티디. |
티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
|
MXPA05000232A
(es)
|
2002-06-21 |
2005-06-17 |
Transform Pharmaceuticals Inc |
Composiciones farmaceuticas con disolucion mejorada.
|
AR039744A1
(es)
*
|
2002-06-26 |
2005-03-09 |
Alza Corp |
Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
|
US20050208132A1
(en)
*
|
2002-07-29 |
2005-09-22 |
Gayatri Sathyan |
Methods and dosage forms for reducing side effects of benzisozazole derivatives
|
CA2493301A1
(en)
*
|
2002-07-29 |
2004-02-12 |
Glaxo Group Limited |
Sustained release formulations comprising lamotrigine
|
CA2494233A1
(en)
*
|
2002-07-29 |
2004-02-05 |
Alza Corporation |
Formulations and dosage forms for controlled delivery of topiramate
|
US20050232995A1
(en)
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
AU2003295846A1
(en)
*
|
2002-11-26 |
2004-06-18 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical formulations of celcoxib
|
US7988993B2
(en)
*
|
2002-12-09 |
2011-08-02 |
Andrx Pharmaceuticals, Inc. |
Oral controlled release dosage form
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
US8183290B2
(en)
*
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
EP2339328A3
(en)
|
2002-12-30 |
2011-07-13 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of celecoxib
|
KR20050095835A
(ko)
*
|
2003-01-14 |
2005-10-04 |
알자 코포레이션 |
조정된 점성층을 갖는 방법 및 제형
|
US20060167435A1
(en)
*
|
2003-02-18 |
2006-07-27 |
Adamis Anthony P |
Transscleral drug delivery device and related methods
|
US7442387B2
(en)
*
|
2003-03-06 |
2008-10-28 |
Astellas Pharma Inc. |
Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
|
US20040214893A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Matthew Peterson |
Gabapentin compositions
|
JP2007502329A
(ja)
|
2003-05-23 |
2007-02-08 |
トランスフォーム・ファーマシューティカルズ・インコーポレイテッド |
セルトラリン組成物
|
US20050058707A1
(en)
*
|
2003-08-06 |
2005-03-17 |
Iran Reyes |
Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
|
KR20060092255A
(ko)
*
|
2003-09-26 |
2006-08-22 |
알자 코포레이션 |
고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
|
MXPA06003453A
(es)
|
2003-09-26 |
2006-08-31 |
Johnson & Johnson |
Barra de empuje oros para el suministro controlado de agentes activos.
|
MXPA06003452A
(es)
|
2003-09-26 |
2006-08-31 |
Johnson & Johnson |
Formulaciones de liberacion controlada que exhiben una velocidad de liberacion ascendente.
|
AU2004275816A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Alza Corporation |
Controlled release formulations of opioid and nonopioid analgesics
|
EP1680083A1
(en)
*
|
2003-10-31 |
2006-07-19 |
ALZA Corporation |
Compositions and dosage forms for ehnanced absorption of iron
|
US20050113410A1
(en)
*
|
2003-11-03 |
2005-05-26 |
Mark Tawa |
Pharmaceutical salts of zafirlukast
|
KR20060109926A
(ko)
|
2003-11-19 |
2006-10-23 |
메타베이시스 테라퓨틱스, 인크. |
새로운 인-함유 갑상선 호르몬 모방약들
|
CA2550699A1
(en)
*
|
2003-12-29 |
2005-07-21 |
Alza Corporation, Inc. |
Novel drug compositions and dosage forms of topiramate
|
EP2292213A1
(en)
|
2004-02-06 |
2011-03-09 |
Cephalon, Inc. |
Compositions comprising a polymorphic form of armodafinil
|
US20050196447A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US20050196446A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US20050196448A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Hai Yong Huang |
Polymeric compositions and dosage forms comprising the same
|
US20050196442A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
WO2005092065A2
(en)
*
|
2004-03-25 |
2005-10-06 |
Transform Pharmaceuticals, Inc. |
Novel tricyclic compounds and related methods of treatment
|
US20050266087A1
(en)
*
|
2004-05-25 |
2005-12-01 |
Gunjan Junnarkar |
Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
|
WO2006007448A2
(en)
*
|
2004-06-17 |
2006-01-19 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions and related methods of use
|
US8541026B2
(en)
*
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
US8779175B2
(en)
*
|
2004-10-25 |
2014-07-15 |
Synthonics, Inc. |
Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
|
WO2006073779A1
(en)
*
|
2004-12-30 |
2006-07-13 |
Transform Phamaceuticals, Inc. |
Novel omeprazole forms and related methods
|
ATE413864T1
(de)
*
|
2005-01-27 |
2008-11-15 |
Alza Corp |
Orale osmotische darreichungsform mit membran mit hoher flussdichte
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
NZ594810A
(en)
*
|
2005-03-15 |
2012-12-21 |
Verenium Corp |
Cellulases, nucleic acids encoding them and methods for making and using them
|
RU2408368C2
(ru)
*
|
2005-06-27 |
2011-01-10 |
Биовэйл Лэборэториз Интернэшнл С.Р.Л. |
Препараты соли бупропиона с модифицированным высвобождением
|
MX2008002795A
(es)
*
|
2005-08-30 |
2009-02-25 |
Nicholas Piramal India Ltd |
Composicion farmaceutica de metformina de liberacion extendida y proceso para producirla.
|
US20090317355A1
(en)
*
|
2006-01-21 |
2009-12-24 |
Abbott Gmbh & Co. Kg, |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
US20090022798A1
(en)
*
|
2007-07-20 |
2009-01-22 |
Abbott Gmbh & Co. Kg |
Formulations of nonopioid and confined opioid analgesics
|
US20100172989A1
(en)
*
|
2006-01-21 |
2010-07-08 |
Abbott Laboratories |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
US20070282010A1
(en)
*
|
2006-05-30 |
2007-12-06 |
Bridge Pharma, Inc. |
Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals
|
CN101453982B
(zh)
|
2006-05-30 |
2011-05-04 |
精达制药公司 |
两件式内部通道渗透递送系统流动调节器
|
US20080070990A1
(en)
*
|
2006-05-30 |
2008-03-20 |
Stirling Products Limited |
Use of ractopamine enantiomers
|
US8703191B2
(en)
*
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
WO2008021133A2
(en)
|
2006-08-09 |
2008-02-21 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies
|
US9114133B2
(en)
|
2006-08-25 |
2015-08-25 |
U.S. Dept. Of Veterans Affairs |
Method of improving diastolic dysfunction
|
US7538652B2
(en)
*
|
2006-08-29 |
2009-05-26 |
International Business Machines Corporation |
Electrical component tuned by conductive layer deletion
|
WO2008089260A2
(en)
*
|
2007-01-16 |
2008-07-24 |
Victory Pharma, Inc. |
Combined administration of benzonatate and guaifenesin
|
MX2009008534A
(es)
|
2007-02-09 |
2009-11-23 |
Metabasis Therapeutics Inc |
Antagonistas novedosos del receptor de glucagon.
|
WO2008103538A1
(en)
*
|
2007-02-21 |
2008-08-28 |
Connected Health Systems, Llc |
Treating adhd and other diseases involving inflammation
|
EP2157967B1
(en)
|
2007-04-23 |
2013-01-16 |
Intarcia Therapeutics, Inc |
Suspension formulations of insulinotropic peptides and uses thereof
|
US8637080B2
(en)
|
2007-06-28 |
2014-01-28 |
Osmotica Kereskedelmi és Szolgáltató, KFT |
Rupturing controlled release device comprising a subcoat
|
CN106279283A
(zh)
|
2007-08-13 |
2017-01-04 |
症变治疗公司 |
新颖的葡糖激酶活化剂
|
AU2008331928B2
(en)
*
|
2007-12-03 |
2012-08-16 |
Bridge Pharma, Inc. |
Use of RR/SR-ractopamine
|
JP2011511782A
(ja)
|
2008-02-12 |
2011-04-14 |
アボット・ラボラトリーズ |
長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
CA2722295C
(en)
*
|
2008-04-29 |
2019-01-15 |
Pharnext |
Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
|
CN102316730A
(zh)
*
|
2008-05-09 |
2012-01-11 |
天雅瑞药业有限公司 |
用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
|
PT2799428T
(pt)
|
2008-08-13 |
2017-02-17 |
Metabasis Therapeutics Inc |
Antagonistas de glicagina
|
CN101703488B
(zh)
*
|
2008-12-16 |
2013-02-20 |
北京科信必成医药科技发展有限公司 |
具有润滑层结构的双层渗透泵控释片及其制备方法
|
CN104323981B
(zh)
|
2009-09-28 |
2019-03-12 |
精达制药公司 |
基本稳态药物递送的快速建立和/或终止
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US20110136815A1
(en)
*
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US8969327B2
(en)
|
2010-04-08 |
2015-03-03 |
Emory University |
Substituted androst-4-ene diones
|
EP2621487B1
(en)
|
2010-09-28 |
2017-05-03 |
Depomed, Inc. |
Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
CA2830069C
(en)
|
2011-03-20 |
2019-11-12 |
The University Of British Columbia |
Therapeutic agent for emphysema and copd
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
US9102105B2
(en)
*
|
2011-09-13 |
2015-08-11 |
Vista Scientific Llc |
Method for forming an ocular drug delivery device
|
CA2924141C
(en)
|
2013-08-22 |
2022-06-07 |
The General Hospital Corporation |
5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase
|
US10076504B2
(en)
|
2014-06-12 |
2018-09-18 |
Ligand Pharmaceuticals, Inc. |
Glucagon antagonists
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
WO2016196851A2
(en)
|
2015-06-03 |
2016-12-08 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
US11437139B2
(en)
|
2015-12-28 |
2022-09-06 |
Data Vault Holdings, Inc. |
Method and apparatus for biometric data collection combining visual data with historical health records metadata
|
US11593764B2
(en)
*
|
2015-12-28 |
2023-02-28 |
Data Vault Holdings, Inc. |
Remote medication delivery systems
|
MX2018014016A
(es)
|
2016-05-16 |
2019-08-01 |
Intarcia Therapeutics Inc |
Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
CN110225762A
(zh)
|
2017-01-03 |
2019-09-10 |
因塔西亚制药公司 |
包括glp-1受体激动剂的连续施用和药物的共同施用的方法
|
USD933219S1
(en)
|
2018-07-13 |
2021-10-12 |
Intarcia Therapeutics, Inc. |
Implant removal tool and assembly
|
US11547670B2
(en)
*
|
2019-03-05 |
2023-01-10 |
Amneal Complex Products Research Llc |
Delayed release methylphenidate compositions
|
RU2754850C1
(ru)
*
|
2020-07-20 |
2021-09-08 |
федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" |
Способ определения скорости высвобождения инкапсулированного в ниосомы цефотаксима in vitro
|